首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Modulation of telomere shelterin by TFR1 and TRF2 interacts with telomerase to maintain the telomere length in non-small cell lung cancer.
【24h】

Modulation of telomere shelterin by TFR1 and TRF2 interacts with telomerase to maintain the telomere length in non-small cell lung cancer.

机译:TFR1和TRF2对端粒庇护素的调节作用与端粒酶相互作用以维持非小细胞肺癌的端粒长度。

获取原文
获取原文并翻译 | 示例
           

摘要

Our previous report demonstrated good correlations between the expressions of h-TERT and its associated genes, such as c-Myc, TRF1 and TRF2. To observe the interaction between telomerase activity and expression of its associated genes in regulation of the telomere restriction fragment length (TRFL) in non-small cell lung cancer (NSCLC), 79 NSCLC specimens were examined. Telomerase activity, h-TERT, TRF1 and TRF2 genes expression were observed in 60.8, 66.7, 74.7, and 83.5% of the tumour tissues, respectively. The TRFL were shorter in both tumour tissues and telomerase positive tissues, as compared to their counterparts. The t-TRFLR (tumour-to-normal TRFL ratio) was also lower in telomerase positive tissues. When telomerase was negative, the t-TRFLR was lower in both TRF1 positive and TFR2 positive. However, when telomerase was positive, the t-TRFLR was only lower in the TFR2 positive group. When t-TRFLR level was equal to or less than 75%, the majority of the specimens became TRF1 and TRF2 positive. To explain these findings, our hypothesis is that when the TRF length becomes shorter during tumour progression, the tumour cells can sustain a better tolerance to shorter telomere with the help of both TRF1 and TRF2, but without immediate activation of the telomerase. However, when the TRF length reaches a critical level, changing the telomere shelterin by persistent expression of the TRF2, which in combination with telomerase activation reverses the telomere shortening.
机译:我们以前的报告证明了h-TERT及其相关基因(例如c-Myc,TRF1和TRF2)的表达之间具有良好的相关性。为了观察端粒酶活性及其相关基因表达之间的相互作用,以调节非小细胞肺癌(NSCLC)的端粒限制性片段长度(TRFL),共检查了79个NSCLC标本。在60.8、66.7、74.7和83.5%的肿瘤组织中分别观察到端粒酶活性,h-TERT,TRF1和TRF2基因表达。与它们的对应物相比,肿瘤组织和端粒酶阳性组织中的TRFL都较短。在端粒酶阳性组织中,t / n-TRFLR(肿瘤与正常TRFL的比率)也较低。当端粒酶阴性时,t / n-TRFLR在TRF1阳性和TFR2阳性中均较低。但是,当端粒酶阳性时,t / n-TRFLR仅在TFR2阳性组中较低。当t / n-TRFLR水平等于或小于75%时,大多数标本变为TRF1和TRF2阳性。为了解释这些发现,我们的假设是,当TRF长度在肿瘤进展过程中变短时,肿瘤细胞可以借助TRF1和TRF2维持对较短端粒的更好耐受性,而不会立即激活端粒酶。但是,当TRF长度达到临界水平时,通过TRF2的持续表达来改变端粒庇护素,而TRF2与端粒酶激活相结合可逆转端粒缩短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号